Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus Anlotinib and Docetaxel in Advanced NSCLC
NCT06141226Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing TQB2450 + Anlotinib + Docetaxel with TQB2450 + Placebo + Docetaxel (2 arms). Primary endpoint: Progression-Free Survival up to 48 weeks. Started Apr 2023; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06141226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141226.